Epizyme’s vision is to rewrite cancer therapy through targeted epigenetic medicines for patients with unsolved diseases. We aspire to change the standard of care for patients and physicians by developing medicines with fundamentally new mechanisms of action.
We are focused on creating medicines that are targeted at specific causes of diseases, that are orally administered, tolerable, easy to take, and that are based on a deep understanding of the patients that will benefit from them.
Since 2011, we have discovered three novel epigenetic therapies, two of which are in clinical development by Epizyme, and one that will be entering the clinic in 2016 by one of our strategic partners.
Our pioneering work in epigenetic drug development is led by the advancement of tazemetostat in a number of cancer indications and treatment settings. Our unique scientific capabilities have enabled us to expand our platform into new epigenetic target classes likely to be highly important in oncology. Our discovery research is yielding exciting new targets for which we are developing novel small molecule programs with the goal of creating a sustainable pipeline of clinical candidates. To help further accelerate our portfolio, we have established a foundation of strategic collaborations with biopharmaceutical leaders.
At Epizyme, our exceptional team is wholly dedicated to bringing epigenetic therapies to the many patients who can benefit from them. We believe that we have the opportunity to change the lives of patients with cancer and are well positioned to deliver on our multi-year vision.